Montelukast%2525252525252520levocetrizine

# Montelukast-Levocetirizine *Note: This combination is often prescribed as two separate agents for synergistic effect in allergic conditions.* ## Overview A combination of a selective, potent cysteinyl leukotriene receptor antagonist (Montelukast) and a third-generation non-sedating H1-receptor antagonist (Levocetirizine). Used to address both the inflammatory and histamine-mediated components of allergic rhinitis and chronic urticaria. ## Primary Indications * Allergic Rhinitis (Seasonal/Perennial) * Chronic Urticaria * Adjunctive therapy for asthma (Montelukast component) ## Adult Dosing * **Montelukast:** 10 mg orally once daily, preferably in the evening. * **Levocetirizine:** 5 mg orally once daily, usually in the evening to minimize daytime somnolence. ## Pediatric Dosing * **Montelukast:** * 6–14 years: 5 mg chewable tablet once daily. * 2–5 years: 4 mg chewable or oral granules once daily. * **Levocetirizine:** * 6–11 years: 2.5 mg once daily (evening). * 12 years and older: 5 mg once daily. ## Dose Adjustments * **Levocetirizine:** Requires renal adjustment. * CrCl 30–49 mL/min: 2.5 mg once daily. * CrCl 10–29 mL/min: 2.5 mg every 48 hours. * ESRD/Dialysis: Contraindicated. * **Montelukast:** No dosage adjustment indicated for renal or mild-to-moderate hepatic impairment. ## Contraindications * **Montelukast:** Hypersensitivity to any component. * **Levocetirizine:** End-stage renal disease (CrCl <10 mL/min) or patients undergoing hemodialysis; hypersensitivity to cetirizine or hydroxyzine. ## Adverse Effects * **Montelukast:** Neuropsychiatric events (agitation, aggression, depression, sleep disturbances, suicidal ideation), headache, upper respiratory infection. * **Levocetirizine:** Somnolence (higher incidence than other 2nd-gen antihistamines), fatigue, nasopharyngitis, dry mouth. ## Key Drug Interactions * **Montelukast:** Strong CYP450 inducers (e.g., Phenytoin, Phenobarbital, Rifampin) may decrease MONT levels; clinical significance is generally minor but monitor for decreased efficacy. * **Levocetirizine:** Central Nervous System (CNS) depressants (alcohol, sedatives) may potentiate sedation. Avoid concurrent use. ## Monitoring * **Neuropsychiatric:** Monitor for mood changes or behavior changes (especially in pediatric patients starting Montelukast). * **Renal:** Re-evaluate renal function if persistent drowsiness occurs with Levocetirizine. * **Symptoms:** Evaluate therapeutic response (reduction in sneezing, rhinorrhea, pruritus) after 2–4 weeks. ## Clinical Pearls * **Neuropsychiatric Warning:** FDA mandates a Boxed Warning for Montelukast regarding serious neuropsychiatric events. Counsel patients/parents to discontinue if abnormal behavior occurs. * **Administration:** Montelukast oral granules may be administered directly in the mouth, dissolved in teaspoon of cold/room temperature baby formula, or breast milk. Do not store once mixed. * **Timing:** While both can be taken at any time, evening dosing helps mitigate peak sedation from Levocetirizine and addresses peak nighttime asthma symptoms for Montelukast. *** *Disclaimer: This information is for educational purposes only. Clinical guidelines and local prescribing protocols vary; always verify drug dosing, contraindications, and potential interactions against current, peer-reviewed clinical databases or institutional formulary guidelines before prescribing or administering medication.*